Related Experiment Video
Updated: May 24, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Costs of paediatric diabetes care in Germany: current situation and comparison with the year 2000
C C Bächle1, R W Holl, K Straßburger
1Institute of Biometrics and Epidemiology, German Diabetes Centre, Leibniz Center at the Heinrich Heine University, Düsseldorf, Germany. christina.baechle@ddz.uni-duesseldorf.de
Insights
Direct costs for pediatric Type 1 diabetes care in Germany rose significantly between 2000 and 2007. This increase in healthcare spending for children with diabetes reflects new treatments and rising prevalence.
Area of Science:
- Pediatric Endocrinology
- Health Economics
- Diabetes Management
Background:
- Type 1 diabetes is a chronic condition requiring ongoing medical care for children.
- Estimating the direct costs of pediatric diabetes care is crucial for resource allocation and policy-making.
- Previous cost estimations for German pediatric diabetes care exist for the year 2000.
Purpose of the Study:
- To determine the direct costs associated with pediatric Type 1 diabetes care in Germany for 2007.
- To identify factors influencing these costs.
- To compare the 2007 costs with those from 2000.
Main Methods:
- Utilized clinical data and healthcare charges from 14,185 children (<20 years) with diabetes from a nationwide patient registry (DPV).
- Monetized healthcare utilization using statutory health insurance fees and prices.
- Analyzed cost associations with age, sex, migration background, diabetes duration, and metabolic control using regression models.
Main Results:
- Mean direct diabetes-associated costs per child were €3524 in 2007.
- Major cost drivers included hospitalization (32%), glucose self-monitoring (29%), insulin pump therapy (18%), and insulin (15%).
- Total direct costs for pediatric diabetes care in Germany exceeded €110 million in 2007, a 47% increase from 2000.
Conclusions:
- Direct costs for pediatric Type 1 diabetes care in Germany increased between 2000 and 2007.
- This rise is likely attributed to the adoption of new therapeutic strategies and an increased prevalence of diabetes.
- Healthcare expenditures for managing pediatric diabetes require ongoing monitoring and evaluation.
Aims:
To estimate direct costs of paediatric Type 1 diabetes care and associated factors in Germany for the year 2007 and to compare results with the costs for the year 2000.
Methods:
Our study includes clinical data and charges for any diabetes-related health care service of 14,185 continually treated subjects with paediatric diabetes aged < 20 years [52.5% male, mean age (SD) 12.1 (4.2) years], derived from a nationwide prospective patient documentation system (DPV). Health-care utilization was valued in monetary terms by using inpatient and outpatient medical fees and retail prices (perspective of the statutory health insurance). Associations between average total diabetes-related costs or various single cost categories per patient and age, sex, migration background, diabetes duration, and metabolic control were analysed by multiple regression procedures and by a two-part model for hospitalization costs. Total direct costs in the whole paediatric diabetes population in Germany were estimated. Mean costs per patient as well as total costs in the German paediatric diabetes population in 2007 were compared to 2000 costs (inflated to the year 2007).
Results:
Mean direct diabetes-associated costs per subject were €3524 (inter-quartile range: 1831-4743). Main cost categories were hospitalization (32%), glucose self-monitoring (29%), insulin pump therapy (18%), and insulin (15%). Based on the present estimation, the total costs of paediatric diabetes care in Germany exceeded €110 million in 2007. Compared with estimates of the year 2000, average costs per patient had increased by 20% and total costs for German paediatric diabetes care by 47%.
Conclusions:
Direct costs for paediatric Type 1 diabetes care increased between 2000 and 2007, probably partly because of new therapeutic strategies and an increase in diabetes prevalence.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Symptoms, Diagnosis, and Complications

